Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8FD
|
|||
| Former ID |
DIB016746
|
|||
| Drug Name |
S-18327
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 1 | [1] | |
| Company |
Servier
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25FN4O2
|
|||
| Canonical SMILES |
C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCN4CCN(C4=O)C5=CC=CC=C5
|
|||
| InChI |
1S/C23H25FN4O2/c24-18-6-7-20-21(16-18)30-25-22(20)17-8-10-26(11-9-17)12-13-27-14-15-28(23(27)29)19-4-2-1-3-5-19/h1-7,16-17H,8-15H2
|
|||
| InChIKey |
ULCAXFRFGIKHRG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 200398-40-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009651) | |||
| REF 2 | S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther. 2000 Jan;292(1):38-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.